49 -2 (40) 2022 — Musashaykhov U.Kh., Musashaykhova Sh.M., — TO OPTIMIZE THE CRITERIA FOR DIAGNOSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BASED ON THE CARRIER POLYMORPHISM OF THE EPIGENETIC REGULATOR GENE, TUMOR SUPPRESSOR TP53

TO OPTIMIZE THE CRITERIA FOR DIAGNOSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BASED ON THE CARRIER POLYMORPHISM OF THE EPIGENETIC REGULATOR GENE, TUMOR SUPPRESSOR TP53

Musashaykhov U.Kh., Andijan State Medical Institute.

Musashaykhova Sh.M., Andijan State Medical Institute.

Boboev K.T. Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan (RSSPMCH of the Ministry of Health of the Republic of Uzbekistan).

Resume

In this study, 31 examined patients with ET were analyzed by examining the frequency of distribution of alleles and genotypes of Pro72Arg polymorphism in the TP53 gene. In both groups, the actual distribution of Pro72Arg polymorphism genotypes in the TP53 gene. It corresponded to what was expected at the Hardy-Weinberg equilibrium (p<0.05). There was a tendency to increase the chance of detecting ET in the presence of an unfavorable genotype of Pro72Arg polymorphism in the TP53 gene by comparison of the control group.

Key words: essential thrombocytemia, genetic polymorphism, Pro72Arg in TP53 gene, CMP, genotype, allele.

First page

260

Last page

263

For citation: Musashaykhov U.Kh., Musashaykhova Sh.M., Boboev K.T. TO OPTIMIZE THE CRITERIA FOR DIAGNOSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BASED ON THE CARRIER POLYMORPHISM OF THE EPIGENETIC REGULATOR GENE, TUMOR SUPPRESSOR TP53 //New Day in Medicine 2(40)2022 260-263 https://cutt.ly/GAFrSJj

LIST OF REFERENCES:

1. Абрамова А.В., Абдуллаев А.О., Азимова М.Х. и соавт. Алгоритмы диагностики и протоколы лечения заболеваний системы крови //В 2 томах, /М.: Практика. –  2018. – Том 2.
2. Ионова Т.И. Значение исследования качества жизни в современном здравоохранении // Качество и жизнь.  –  2019 . – Т.1, № 21.  – С. 3–8.
3. Busque L., Porwit A., Day R. et al. Laboratory investigation of myeloproliferative neoplasms (MPNs): Recommendations of the Canadian MPN Group. //Am J Clin Pathol. 2016; 146: 408 – 22. doi: 10.1093/ajcp/aqw131.
4. Кузнецова П.И., Меликян А.Л., Суборцева И.Н. и соавт. Особенности цереброваскулярной патологии при миелопролиферативных заболеваниях // Гематология и трансфузиология. –2016. – Т. 61,  №1. – С. 20.
5. Barbui T., Thiele J., Gisslinger H. et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. //BloodCancer J. 2018; 8(2): 15. doi: 10.1038/s41408-018-0054-y.
6. Танашян М.М., Кузнецова П.И., Лагода О.В. и соавт. Миелопролиферативные заболевания и ишемический инсульт // Анналы клинической и экспериментальной неврологии. –2014. – №8. – С.41–45.
7. MPN Group. Am J Clin Pathol. 2016; 146: 408 – 22. doi: 10.1093/ajcp/aqw131.
8. Goel S., Paoli C., Iurlo A. et al. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. //Eur J Haematol. England. 2017; 99(1): 36–41. doi: 10.1111/ejh.12887.